Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimian Group ABFRA:0V0 +1.13%68 FCF Yield % is 6.30 as of Jul. 13, 2026, which is 1753% above its 10-year median of 0.34. GuruFocus rates FRA:0V0 with a GF Score™ of 68/100 and a GF Value™ of €3.08 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 86.38% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Vimian Group AB's FCF Yield % or its related term are showing as below:
FRA:0V0'
s FCF Yield % Range Over the Past 10 Years
Min: -5.77 Med: 0.34 Max: 7.44
Current: 6.3
During the past 9 years, the highest FCF Yield % of Vimian Group AB was 7.44%. The lowest was -5.77%. And the median was 0.34%.
FRA:0V0's FCF Yield % is ranked better than 86.38% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.36
vs FRA:0V0: 6.30
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vimian Group AB FCF Yield % Related Terms
Vimian Group AB FCF Yield % Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vimian Group AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (FRA:0V0) has a FCF Yield % of 6.30 as of Jul. 13, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vimian Group AB and its competitors. This is 1753% above median its historical median of 0.34. According to the industry distribution chart, Vimian Group AB ranks #29 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 13.6%.
Is Vimian Group AB's FCF Yield % too high?
Vimian Group AB's current FCF Yield % of 6.30 is 1753% above median its 10-year median of 0.34. Based on the distribution chart, Vimian Group AB ranks #29 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vimian Group AB has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #29 out of 213 companies for FCF Yield %. This places Vimian Group AB in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vimian Group AB and its competitors. Vimian Group AB's current FCF Yield % is 6.30, which is 1753% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Based on GuruFocus' analysis, Vimian Group AB (FRA:0V0) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.08, compared to a current price of €2.69 — trading 12.7% below its estimated fair value. The current FCF Yield % is 6.30, which is 1753% above median its 10-year median of 0.34. Vimian Group AB's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Vimian Group AB (FRA:0V0), the current FCF Yield % is 6.30 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (FRA:0V0) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of €2.69 is trading 12.7% below its estimated GF Value™ of €3.08.
GuruFocus considers Vimian Group AB to be Modestly Undervalued.
Key valuation signals for FRA:0V0:
FCF Yield %: 6.30 (1753% above median its 10-year median of 0.34)
GF Value™: €3.08 vs. price of €2.69 (12.7% below fair value)
No single metric tells the full story. See the FRA:0V0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
68GF Score
Get the complete analysis for FRA:0V0
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0V0 has been successfully added to your 
